The Predictive Value of 2D Myocardial Strain for Epirubicin-Induced Cardiotoxicity.
Journal
Journal of oncology
ISSN: 1687-8450
Titre abrégé: J Oncol
Pays: Egypt
ID NLM: 101496537
Informations de publication
Date de publication:
2020
2020
Historique:
received:
26
04
2020
revised:
06
09
2020
accepted:
11
11
2020
entrez:
18
12
2020
pubmed:
19
12
2020
medline:
19
12
2020
Statut:
epublish
Résumé
Although epirubicin has significantly improved outcome in breast cancer (BC) patients, it is responsible for myocardial dysfunction that affects patients' quality of life. The use of 2D global longitudinal strain (GLS) has been reported to detect early myocardial dysfunction. The aim of this study was to evaluate how GLS changes can predict cardiotoxicity. We conducted a prospective study from March 2018 to March 2020 on 66 patients with no cardiovascular risk factors, who presented with BC and received epirubicin. We measured left ventricular ejection fraction (LVEF) and GLS before chemotherapy, at three months (T3), and at 12 months (T12) from the last epirubicin infusion. Chemotherapy-Related-Cardiac-Dysfunction (CTRCD) was defined as a decrease of 10% in LVEF to a value below 53% according to ASE and EACI 2014 expert consensus. The mean age at diagnosis was 47 ± 9 years old. At baseline, median LVEF was 70% and median GLS was -21%. Shortly after chemotherapy completion, two patients presented with symptomatic heart failure while asymptomatic CTRCD was revealed in three other patients at T12. Three months after the last epirubicin infusion, median LVEF was 65%, median GLS was -19%, and median GLS variation was 5%. However, in patients who presented with subsequent CTRCD, median GLS at T3 was -16% and median GLS variation was This was the first North African study that assesses the value of measuring GLS to early detect cardiotoxicity. Patients whose GLS remained decreased after 3 months from anthracyclines-base chemotherapy had an increased risk for developing subsequent CTRCD. Further studies with larger sample size are warranted to identify the best cardioprotective molecules to be initiated in these patients before LVEF declines.
Identifiants
pubmed: 33335549
doi: 10.1155/2020/5706561
pmc: PMC7723482
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5706561Informations de copyright
Copyright © 2020 Ichrak Ben Abdallah et al.
Déclaration de conflit d'intérêts
All authors declare that they have no conflicts of interest regarding the publication of this article.
Références
Echocardiography. 2017 Nov;34(11):1601-1609
pubmed: 28895191
Rheumatology (Oxford). 2007 Dec;46(12):1824-7
pubmed: 18032540
J Pharmacol Sci. 2006 Jun;101(2):151-8
pubmed: 16766856
J Clin Oncol. 2016 Jul 1;34(19):2239-46
pubmed: 27091709
Eur J Heart Fail. 2018 Oct;20(10):1454-1456
pubmed: 29972283
Sante Publique. 2016 May-Jun;28(3):331-40
pubmed: 27531431
Bull Cancer. 2008 Feb;95(2):E5-9
pubmed: 18304901
Ultrasound Med Biol. 2015 Mar;41(3):627-43
pubmed: 25619777
Cardiovasc Drugs Ther. 2017 Feb;31(1):63-75
pubmed: 28185035
Eur Heart J Cardiovasc Imaging. 2015 Sep;16(9):977-84
pubmed: 25925220
Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):105-13
pubmed: 20728697
Breast Cancer Res Treat. 2015 Jul;152(1):67-76
pubmed: 26017071
Arq Bras Cardiol. 2018 Mar;110(3):219-228
pubmed: 29694546
J Am Coll Cardiol. 2014 Jul 1;63(25 Pt A):2751-68
pubmed: 24703918
J Clin Oncol. 2017 Mar 10;35(8):893-911
pubmed: 27918725
J Clin Oncol. 1998 Nov;16(11):3502-8
pubmed: 9817267
Br J Cancer. 2010 Mar 16;102(6):1003-9
pubmed: 20179710
Curr Oncol Rep. 2018 Apr 30;20(7):52
pubmed: 29713898
BMC Cancer. 2018 Oct 25;18(1):1037
pubmed: 30359235
J Natl Cancer Inst. 2019 Dec 1;111(12):1298-1306
pubmed: 31093668
Breast Care (Basel). 2019 Dec;14(6):344-353
pubmed: 31933579
Can J Cardiol. 2016 Jul;32(7):908-20
pubmed: 27179544
Cancer Radiother. 2011 Oct;15(6-7):495-503
pubmed: 21885320
Oncol Res. 2017 Sep 21;25(8):1223-1229
pubmed: 28256194
JACC Cardiovasc Imaging. 2018 Aug;11(8):1098-1105
pubmed: 29909105